Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (Q45721339)

2 July 2019

title

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (English)

1 reference

2 July 2019

author

Michael Gnant

1

1 reference

PubMed ID

23425564

15 December 2017

Kathleen I. Pritchard

20

1 reference

15 December 2017

2

Jose Baselga

1 reference

15 December 2017

7

Gabriel N Hortobagyi

1 reference

2 July 2019

Hope Rugo

3

object named as

Hope S Rugo

1 reference

2 July 2019

Hiroji Iwata

10

object named as

Hiroji Iwata

1 reference

2 July 2019

Tarek Sahmoud

17

object named as

Tarek Sahmoud

1 reference

2 July 2019

Shinzaburo Noguchi

4

1 reference

2 July 2019

Howard A Burris

5

1 reference

2 July 2019

Martine Piccart

6

1 reference

2 July 2019

Janice Eakle

8

1 reference

2 July 2019

Hirofumi Mukai

9

1 reference

2 July 2019

Matthias Geberth

11

1 reference

2 July 2019

Lowell L Hart

12

1 reference

2 July 2019

Peyman Hadji

13

1 reference

2 July 2019

Mona El-Hashimy

14

1 reference

2 July 2019

Shantha Rao

15

1 reference

2 July 2019

Tetiana Taran

16

1 reference

2 July 2019

David Lebwohl

18

1 reference

2 July 2019

Mario Campone

19

1 reference

2 July 2019

language of work or name

English

0 references

publication date

19 February 2013

1 reference

2 July 2019

Journal of the National Cancer Institute

published in

1 reference

2 July 2019

volume

105

1 reference

2 July 2019

page(s)

654-663

1 reference

2 July 2019

issue

9

1 reference

2 July 2019

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

cites work

1 reference

12 December 2020

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

12 December 2020

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

1 reference

12 December 2020

Steroidal side effects of exemestane

1 reference

12 December 2020

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

12 December 2020

M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase

1 reference

12 December 2020

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

12 December 2020

Aromatase inhibitors for breast cancer in postmenopausal women

1 reference

12 December 2020

The TOR pathway: a target for cancer therapy

1 reference

12 December 2020

Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

1 reference

12 December 2020

Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment

1 reference

12 December 2020

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

12 December 2020

Activation of PI3K/Akt signaling and hormone resistance in breast cancer

1 reference

12 December 2020

Cumulative incidence in competing risks data and competing risks regression analysis

1 reference

12 December 2020

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

12 December 2020

mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours

1 reference

12 December 2020

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

1 reference

12 December 2020

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women

1 reference

12 December 2020

Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen

1 reference

12 December 2020

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

1 reference

12 December 2020

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

1 reference

12 December 2020

Choice and interpretation of statistical tests used when competing risks are present

1 reference

12 December 2020

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

1 reference

12 December 2020

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

1 reference

12 December 2020

The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial

1 reference

12 December 2020

Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells.

1 reference

12 December 2020

Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis

1 reference

12 December 2020

Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells

1 reference

12 December 2020

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

1 reference

12 December 2020

Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

1 reference

12 December 2020

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies

1 reference

12 December 2020

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

1 reference

12 December 2020

Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties.

1 reference

12 December 2020

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

1 reference

12 December 2020

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

12 December 2020

Skeletal complications of malignancy

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJT026

1 reference

2 July 2019

PMCID

6430494

1 reference

2 July 2019

PubMed ID

23425564

1 reference

2 July 2019